Bell's palsy (BP) is characterized by idiopathic acute weakness of the facial muscles associated with compression of the facial nerve. The present prospective study sought to evaluate the clinical efficacy of ultrasound-guided combined perineural and intramuscular dextrose injection for management of refractory Bell's palsy. The study included 30 patients with Bell's palsy with House-Brackmann scale ≥ 3 who were refractory to standard medical treatment after 3 months of disease onset. They received ultrasound-guided combined perineural and intramuscular dextrose injection. Clinical outcome was assessed using the House-Brackmann scale.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
House Brackmann scale
Timeframe: 3 months